Mason Street Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-2,969
| Closed | -$1.73M | – | 160 |
|
|
2020
Q4 | $1.73M | Sell |
2,969
-35
| -1% | -$19.9K | 0.03% | 706 |
|
|
2020
Q3 | $1.55M | Sell |
3,004
-47
| -2% | -$23.8K | 0.03% | 642 |
|
|
2020
Q2 | $1.38M | Sell |
3,051
-8,442
| -73% | -$3.73M | 0.03% | 678 |
|
|
2020
Q1 | $4.03M | Hold |
11,493
| – | – | 0.09% | 200 |
|
|
2019
Q4 | $4.25M | Buy |
11,493
+221
| +2% | +$77.9K | 0.08% | 249 |
|
|
2019
Q3 | $3.75M | Buy |
11,272
+594
| +6% | +$194K | 0.08% | 271 |
|
|
2019
Q2 | $3.34M | Sell |
10,678
-30
| -0.3% | -$8.98K | 0.07% | 320 |
|
|
2019
Q1 | $3.27M | Buy |
10,708
+160
| +2% | +$43.2K | 0.07% | 317 |
|
|
2018
Q4 | $2.45M | Buy |
10,548
+258
| +3% | +$69.2K | 0.06% | 359 |
|
|
2018
Q3 | $3.22M | Sell |
10,290
-98
| -0.9% | -$30.4K | 0.07% | 317 |
|
|
2018
Q2 | $3M | Buy |
10,388
+235
| +2% | +$64.9K | 0.07% | 329 |
|
|
2018
Q1 | $2.54M | Buy |
10,153
+194
| +2% | +$49.4K | 0.06% | 402 |
|
|
2017
Q4 | $2.38M | Sell |
9,959
-24
| -0.2% | -$5.82K | 0.05% | 435 |
|
|
2017
Q3 | $2.22M | Sell |
9,983
-186
| -2% | -$41.9K | 0.05% | 449 |
|
|
2017
Q2 | $2.3M | Buy |
10,169
+347
| +4% | +$75.6K | 0.06% | 426 |
|
|
2017
Q1 | $1.96M | Buy |
9,822
+134
| +1% | +$25.8K | 0.05% | 487 |
|
|
2016
Q4 | $1.77M | Buy |
9,688
+131
| +1% | +$22.3K | 0.05% | 522 |
|
|
2016
Q3 | $1.57M | Buy |
9,557
+39
| +0.4% | +$5.92K | 0.04% | 551 |
|
|
2016
Q2 | $1.36M | Buy |
9,518
+443
| +5% | +$63.2K | 0.04% | 607 |
|
|
2016
Q1 | $1.24M | Buy |
9,075
+366
| +4% | +$48K | 0.04% | 642 |
|
|
2015
Q4 | $1.21M | Buy |
8,709
+206
| +2% | +$28.6K | 0.04% | 622 |
|
|
2015
Q3 | $1.14M | Buy |
8,503
+119
| +1% | +$17.1K | 0.04% | 638 |
|
|
2015
Q2 | $1.26M | Buy |
8,384
+62
| +0.7% | +$8.87K | 0.04% | 623 |
|
|
2015
Q1 | $1.13M | Sell |
8,322
-14,614
| -64% | -$1.81M | 0.03% | 696 |
|
|
2014
Q4 | $2.77M | Sell |
22,936
-1,111
| -5% | -$128K | 0.02% | 824 |
|
|
2014
Q3 | $2.73M | Buy |
24,047
+209
| +0.9% | +$24.8K | 0.02% | 797 |
|
|
2014
Q2 | $2.85M | Buy |
23,838
+1,637
| +7% | +$200K | 0.02% | 781 |
|
|
2014
Q1 | $2.84M | Buy |
22,201
+896
| +4% | +$115K | 0.02% | 784 |
|
|
2013
Q4 | $2.63M | Buy |
21,305
+13,345
| +168% | +$1.63M | 0.02% | 802 |
|
|
2013
Q3 | $936K | Buy |
7,960
+20
| +0.3% | +$2.36K | 0.01% | 974 |
|
|
2013
Q2 | $891K | Buy |
+7,940
| New | +$931K | 0.01% | 931 |
|
Other funds holding BIO
Mason Street Advisors's BIO Position: Q1 2021 in Review
Mason Street Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2021, closing a stake of 2,969 shares — an estimated $1.73M sold.
Mason Street Advisors first reported a position in BIO in Q2 2013 and held it in 31 quarters. The position peaked at $4.25M in Q4 2019. 491 funds tracked by Wall St. Rank hold BIO as of Q1 2021.
- Mason Street Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q1 2021 after selling out during the quarter.
- Mason Street Advisors sold 2,969 Bio-Rad Laboratories Class A shares in Q1 2021, an estimated $1.73M.
- Mason Street Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 31 quarters.
- Mason Street Advisors's Bio-Rad Laboratories Class A position peaked at $4.25M in Q4 2019.
- 491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2021.
Based on Mason Street Advisors's 13F filing for Q1 2021, filed 14 May 2021.